Abstract 1724P
Background
In Botswana, 65% of breast cancers present at an advanced stage due to multifactorial delays. The WHO Global Breast Cancer Initiative recommends a maximum of 60 days of lead time in diagnostic workup and strongly advocates for the use of patient Navigation. A Patient Navigation Project was created to improve the timely diagnosis and treatment of breast cancer patients around Gaborone, the capital.
Methods
A 2-day theoretical and practical course was delivered in March 2022 to 15 clinical navigators (nurses from 6 district Hospitals and from the Referral Hospital) and 7 non-clinical navigators (advocacy groups). A navigation coordinator served as the point of contact, reported on program outcomes and provided smartphone airtime. Different virtual communication groups were created with navigators to accelerate patient flow and facilitate problem solving.
Results
Between April 2022 and July 2023, 75 patients were included in the navigation program: 21 were in early stages (stages I and II) (28%) and 53 in advanced stages (stages 3 and 4) (71%). From those patients, 46% received neoadjuvant chemotherapy, 17% adjuvant chemotherapy and 25% palliative therapy. Navigation enabled faster access to CT-scan staging, unveiling more stage IV disease (23%), thus avoiding inappropriate curative treatments.
Table: 1724P
Key navigation challenges and improvements
Key persistent challenges | Key improvements |
Delays in biopsy (needle shortages) | Biopsies and staging done locally, avoiding referral delays for diagnostic workup |
Delays in obtaining biopsy and IHC results (pathology backlogs, loss of sample, reagent shortages) | Fast referral pathway for patients in need of urgent consultation |
Patient transport issues | Closer tracking of patients and tests results |
Treatment delays: Stock-outs of drugs (hormone therapy, chemotherapy) and radiation therapy delays | Facilitated access to counselling and transport services |
Time constraints: Limited time allocated to navigation | Increased multidisciplinary collaboration |
Conclusions
The Botswana Breast Cancer Navigation project succeeded in implementing Cancer Navigation in accordance with international guidelines. It improved management of breast cancer patients through a smoother access to diagnosis and treatment, and it addressed barriers to care for specific situations. Many navigation sites referred patients with upfront biopsy diagnosis and minimal staging, and this reduced the time from first consultation in breast clinic to treatment (median delay 22 days). Dr Migeotte and Dr Soares de Pinho contributed equally to this work.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Botswana-Rutgers Partnership for Health.
Funding
UICC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23